SCHEMBL7944901

SCHEMBL7944901

CCC(O)(CC)C(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
KMT2A Q03164 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
MAPK1 P28482 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
MEN1 O00255 1/20 0.49
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
LMNA P02545 3/20 0.46
HCAR2 Q8TDS4 1/20 0.46
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
MAOB P27338 1/20 0.44
PTPRC P08575 1/20 0.43
PTPN1 P18031 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9782112 0.90 ALDH1A1 (0.50) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL638420 0.84 ALDH1A1 (0.55) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL6108042 0.84 ALDH1A1 (0.58) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL535585 0.83 ALDH1A1 (0.53) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL28836748 0.82 ALDH1A1 (0.49) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL11015123 0.82 ALDH1A1 (0.56) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL116845 0.82 ALDH1A1 (0.56) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
Ammonia Solution, Strong SCHEMBL27875656 0.82 ALDH1A1 (0.56) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL24347012 0.81 ALDH1A1 (0.60) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL3756497 0.81 ALDH1A1 (0.60) ALDH1A1KMT2ATDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492182-B2 Hydroxytriazine compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2025-12-09 US disclosed
US-20240076278-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2024-03-07 US disclosed
EP-4046991-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Japan Tobacco Inc. (JP) 2022-08-24 EP disclosed
CN-108137515-B Hydroxy triazine compound and medical use thereof 日本烟草产业株式会社 2021-07-06 CN disclosed
US-20210024486-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2021-01-28 US disclosed
US-20210024486-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2021-01-28 US disclosed
EP-3339296-A1 HYDROXYTRIAZINE COMPOUND AND MEDICAL USE THEREOF Japan Tobacco, Inc. (JP) 2018-06-27 EP disclosed
EP-3339296-A1 HYDROXYTRIAZINE COMPOUND AND MEDICAL USE THEREOF Japan Tobacco, Inc. (JP) 2018-06-27 EP disclosed
CN-108137515-A Hydroxy triazine compound and medical use thereof 日本烟草产业株式会社 2018-06-08 CN disclosed
US-20170057943-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2017-03-02 US disclosed
US-20170057943-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2017-03-02 US disclosed
US-20170057943-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2017-03-02 US disclosed
US-6242514-B1 CYCLIC PHOSPHATE OR PHOSPHONATE; HEAT AND OXIDATION STABILIZER ESPECIALLY FOR OLEFIN POLYMERS AND ENGINEERING THERMOPLASTICS SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2001-06-05 US disclosed
US-5914361-A IMPART HEAT STABILITY TO ORGANIC MATERIALS, INCLUDING POLYOLEFINS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-06-22 US disclosed
US-5830936-A THERMAL STABILIZERS FOR POLYOLEFINS AND ENGINEERING PLASTICS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024486-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF PTGS1, PTGIS, PTGES ALDH1A1 618/4885KMT2A 3316/4885TDP1 391/4885
US-20240076278-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF PTGS1, PTGIS, PTGES ALDH1A1 618/4885KMT2A 3316/4885TDP1 391/4885
US-12492182-B2 Hydroxytriazine compounds and pharmaceutical use thereof PTGS1, PTGIS, PTGES ALDH1A1 618/4885KMT2A 3316/4885TDP1 391/4885
US-20170057943-A1 HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF PTGS1, PTGIS, PTGES ALDH1A1 618/4885KMT2A 3316/4885TDP1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.